ClinicalTrials.gg
RecruitingNCT07301320REBOUNDUpdated May 6, 2026

Epetraborole in Patients With Mycobacterium Abscessus Lung Disease

A Phase 2 interventional study of Epetraborole and Epetraborole in Mycobacterium Abscessus Infection, sponsored by Kevin Winthrop. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Kevin Winthrop · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Mycobacterium Infections, Nontuberculous with a site in United States — 7 open to participants now, 7 under way, none of them phase 3. Mycobacterium Infections, Nontuberculous · United States.

Planned enrollment
7th of 18
84 · median 58
Started
2026
with 1 other
Phase 2
10 of 24
3 open now
Registered
24th of 24
by date
Lead sponsor
3 of 24
Kevin Winthrop

Among the 24 studies in Mycobacterium Infections, Nontuberculous with a site in United States, this one is the 7th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2026, is one of 10 in phase 2, and was the 24th registered.

Mycobacterium Infections, Nontuberculous

54 studies on the registry are indexed under Mycobacterium Infections, Nontuberculous; 19 are open to participants now.

Browse Mycobacterium Infections, Nontuberculous studies →

Open to participants now

7 of the 24 studies in Mycobacterium Infections, Nontuberculous with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Mycobacterium Infections, Nontuberculous studies recruiting now, 8 (67%) set no upper age limit and 2 (17%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Mycobacterium Infections, Nontuberculous with a site in United States, or all of them as a file.
02

Study summary

This double-blind, randomized, placebo-controlled, parallel-group, multicenter, prospective, investigator-initiated trial will evaluate epetraborole (EBO) monotherapy in the treatment of adults with Mycobacterium abscessus complex (MABc) Lung Disease (LD) of mild to moderate severity. For this study, two EBO oral dose regimens will be studied in patients with MABc-LD, each compared to a placebo group (ie, 4 treatment groups): 500 mg daily and 750 mg daily. Detailed inclusion and exclusion criteria attempt to identify only those patients who have acceptable risks based upon the EBO preclinical findings, phase 1, phase 2, and Phase 3 experience; standard-of-care procedures; and the specified procedures of the study. Following receipt of informed consent, and a Screening period, eligible patients will be randomized to one of the 4 treatment groups to receive active or matched placebo EBO tablets for 84 days. Patients will be assessed for clinical and microbiological evidence of efficacy. At selected investigative sites, patients will undergo sparse PK sampling. Safety and tolerability will be determined by standard clinical and laboratory assessment, with oversight by a qualified and appropriately constituted Data Safety Monitoring Board (DSMB). Data collected during the study will be analyzed per a comprehensive Statistical Analysis Plan (SAP). The study will be registered on clinicaltrials.gov. The total duration of patient participation is approximately 6 months.

Read the detailed description

Non-tuberculous mycobacterial lung disease (NTM-LD) is a chronic, debilitating disease that can cause significant morbidity and mortality, and reduces quality of life. The primary intervention to treat NTM-LD is antibiotic treatment to eliminate the causative pathogen and thereby prevent progression of NTM-associated lung destruction and respiratory compromise. Among NTM organisms causing pulmonary infection, Mycobacterium abscessus complex (MABc) LD requires particularly complicated, prolonged and onerous intravenous treatment regimens that are burdensome to patients. New therapeutic options, especially those that can be administered orally, represent a high unmet need.

Epetraborole (EBO), a boron-containing heterocycle also possessing amine and hydroxyl functional groups, blocks bacterial protein synthesis by inhibiting bacterial LeuRS. Epetraborole is active against Mycobacterium abscessus complex (MABc) organisms in vitro, including against isolates resistant to drugs commonly used to treat MABc-Lung Disease (LD) (e.g., clarithromycin and amikacin). To date, no clinical efficacy data are available for use of EBO in humans with MABc-LD. However, available nonclinical and PK data support the potential efficacy of EBO in MABc-LD. A Phase 1 human lung PK study in healthy volunteers showed that the exposure of EBO in alveolar (lung) macrophages, lung cells that are primarily infected with mycobacteria in NTM-LD, was approximately 5-fold higher than in plasma. EBO exposure in pulmonary epithelial lining fluid (ELF) is approximately 53% of that in plasma. Because NTM organisms may also be found in ELF, adequate EBO concentrations in that space are potentially important to achieve therapeutic success. Furthermore, PK/PD modeling data support the potential efficacy of EBO for treatment of MABc-LD. Since the EBO MIC90 for MABc isolates is \~256-fold lower than that observed for MAC isolates from the truncated EBO-301 Phase 2/3 study in treatment-refractory Mycobacterium avium complex lung disease, treatment outcomes in MABc-LD are expected to be favorable. The molecule therefore has the potential to address the unmet need in MABc-LD patients with limited treatment options.

For this study, two oral EBO dose regimens will be studied in patients with MABc-LD compared to placebo: 500 mg daily and 750 mg daily.

03

Conditions studied

  • Mycobacterium Abscessus Infection

Keywords

  • NTM
  • nontuberculous mycobacteria
  • Mycobacterium abscessus
  • M. abscessus
  • abscessus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients who are 18 years of age or older.
  2. Willing and able to provide written .
  3. Patients with MABc lung disease, meeting the following (a) Microbiological, (b) Clinical, (c) Radiographic

    a. Microbiological criteria: i. Documentation of at least 1 Pre-Study MABc-positive respiratory specimen (sputum or deep bronchial specimen) collected per standard of care within 6 months prior to signing the consent form.

    ii. At least 1 Screening MABc-positive expectorated or induced sputum sample. b. Clinical criteria: At least 2 of the following patient-reported clinical symptoms: i. Chest pain ii. Chronic cough iii. Coughing up blood iv. Fatigue v. Fever (documented by thermometer) vi. Mucus (sputum) production vii. Night sweats (drenching perspiration with no other obvious etiology, e.g. perimenopausal) viii. Poor appetite ix. Shortness of breath x. Weight loss (unintentional, more than 5% of usual weight in 6 to 12 months) c. Radiographic criteria: Non-contrast chest CT scan within 4 months prior to signing the ICF (Pre-Study chest CT) or within the Screening Period (Screening chest CT) with abnormalities consistent with MABc-LD based on local interpretation (e.g. Investigator or local radiologist).

  4. Patients who, in the opinion of the investigator, will not require initiation of guideline-directed antibiotic therapy for treatment of MABc-LD within the next 6 months, and for whom a delay, in order for the subject to participate in a placebo-controlled clinical trial, is considered both reasonable and clinically acceptable.
  5. Patients who are willing to comply with all the study activities and procedures throughout the duration of the study.

    1. Patients must agree to use an effective method of , if applicable, as follows: Females of (FOCPs; defined in Appendix 1, Contraception Requirements) must commit to either sexual abstinence or use of at least 2 medically accepted, effective methods of birth control (defined in Contraception Requirements) from Screening through the EOS Visit
    2. Males who are sexually active with a FOCP must agree to use an effective barrier method of contraception (defined in Contraception Requirements) from Screening through the EOS Visit
  6. Patients expected to survive with continued antimycobacterial therapy and appropriate supportive care from Screening through the LFU Visit, in the judgment of the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a presence of any suspected or confirmed disease or condition at Screening or the time of randomization that, in the opinion of the Investigator, may confound the assessment of symptom-based clinical response, including, but not limited to, the following:

    • Radiographic presence of cavitary disease (defined as a patient with one or more cavities >2 cm internal diameter)
    • Cystic fibrosis or other inherited disorders of airway ciliary dysfunction (e.g., primary ciliary dyskinesia)
    • Active allergic bronchopulmonary mycosis
    • Anticipated or planned lung surgery for treatment of MABc lung disease
    • Disseminated MABc infection, or other known or suspected non-pulmonary source of infection (e.g., infective endocarditis, osteomyelitis, meningitis, or urinary tract infection) requiring non-study antimicrobial therapy
    • Concomitant pulmonary infection requiring antimicrobial therapy, including infection caused by fungi, viruses, non-MABc mycobacteria (e.g., Mycobacterium tuberculosis, Mycobacterium avium intracellulare, Mycobacterium avium complex, Mycobacterium kansasii), or other bacteria (e.g., Pseudomonas aeruginosa, Staphylococcus aureus).

    Note: Patients with MABc lung disease and concomitant non-MABc lung infection requiring antimicrobial therapy must complete the antimicrobial treatment for the non-MABc infection prior to randomization. Patients with respiratory specimen cultures that contain growth of non-MABc organisms that are deemed by the Investigator to be respiratory tract colonizers and who do not require or receive specific antimicrobial therapy may remain eligible. The Investigator should discuss such cases with the Study Investigator prior to randomization and provide rationale for study eligibility in the source document.

  2. Patients on brensocatib who have not been on a stable dose for at least 12 weeks.
  3. Patients with active pulmonary (primary or ) or any malignancy that required or would require chemotherapy or radiation therapy within 1 year prior to randomization through the LFU Visit.
  4. Patients with (CrCl) of \<30 mL/min, as estimated by the Cockcroft-Gault formula, at Screening: Estimated CrCl (mL/min) = (140 - Age [years]) × Actual Body Weight [kg] × [0.85 if Female]) / (72 × Serum Creatinine [mg/dL]).
  5. Patients with any of the following hematological findings:

    1. \<11.0 g/dL or \<6.83 mmol/L.
    2. Donation of blood or plasma within 28 days prior to randomization; or symptomatic loss of blood or hemorrhage within 28 days prior to randomization.
    3. Pre-existing (inborn or acquired) disorder of hematopoiesis that could substantially worsen the effect of EBO on hemoglobin levels or potentially prevent hemoglobin recovery post cessation of treatment, for example, thalassemia, sickle cell disease, hemolytic anemia, Inherited bone marrow failure syndromes, myelodysplastic or myeloproliferative disorders, bone marrow transplantation
  6. Patients with severe hemoptysis within 28 days prior to randomization, defined as >100 mL (approximately >7 tbsp blood) over any 24-hour period.
  7. Patients with severe hepatic impairment, as evidenced by (ALT) or aspartate aminotransferase (AST) >3 × (ULN) or total >2 × ULN, or clinical signs of cirrhosis or end-stage hepatic disease (e.g., ascites, hepatic encephalopathy).
  8. Patients who are pregnant or breastfeeding.
  9. Patients with a mean corrected using Fridericia's formula (QTcF) >500 msec based 12-lead at Screening.
  10. Patients with an immunodeficiency or an condition and risk for an opportunistic pulmonary infection, including:

    • History of lung transplantation
    • Known history of (HIV) infection plus either an active acquired immunodeficiency syndrome (AIDS)-defining illness in the past 12 months, or a known cluster of differentiation 4 (CD4) count \<200/mm3 within the past 12 months
    • Neutropenia at Screening ( \<1,000 neutrophils/mm3)
    • Use of immunosuppressive therapy at Screening that in the opinion of the Investigator may place the patient at risk for an opportunistic pulmonary infection, including transplant rejection medication and chronic systemic defined as ≥15 mg/day of prednisone or systemic equivalent for >4 weeks.
  11. Patients with an anticipated start of new non-study antimycobacterial therapy to be administered at any time between Screening and EOT.
  12. Patients who have participated in a clinical trial of an agent within 30 days (or 5 half-lives, whichever is longer) prior to Screening.
  13. Patients with any prior exposure to epetraborole.
  14. Patients with any condition that, in the opinion of the Investigator, interferes with the ability to safely complete the study or adhere to study requirements, including the patient's inability or unwillingness to comply with all study assessments and visits.
  15. Patients with to any EBO (e.g., microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc).
  16. Patients with a history of eosinophilic interstitial pneumonitis

For eligibility purposes, vital signs, clinical laboratory tests, and ECGs may be repeated once if an abnormal result is observed at the initial reading during Screening.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    High Dose Epetraborole

    This arm is a daily treatment regimen of a 750mg oral dose of Epetraborole.

    Drug: Epetraborole

  • Experimental
    Low Dose Epetraborole

    This arm is a daily treatment regimen of a 500mg oral dose of Epetraborole.

    Drug: Epetraborole

  • Placebo comparator
    High Dose Placebo

    This arm is a daily treatment regimen of a placebo, matching the high dose experimental arm.

    Drug: Placebo

  • Placebo comparator
    Low Dose Placebo

    This arm is a daily treatment regimen of a placebo, matching the low dose experimental arm.

    Drug: Placebo

Interventions

  • High-dose intervention (750mg daily)

  • Low-dose intervention (500mg daily)

  • DrugPlacebo

    Placebo intervention (matching the high-dose experimental intervention)

  • DrugPlacebo

    Placebo intervention (matching the low-dose experimental intervention)

06

What researchers measure

Primary outcomes

  1. Clinical Response (NTM Symptom Evaluation Instrument) at Day 84

    Improvement in severity of at least 50% of the symptoms present at baseline and no deterioration in severity of symptoms present at baseline

    Time frame: Day 1 to Day 84

  2. Sputum culture conversion by Day 84

    Defined as 3 consecutive negative cultures one month apart without intervening or subsequent positives

    Time frame: Day 1 to Day 84

  3. Decrease in semi-quantitative sputum culture counts at Day 84

    Defined as improvement in sputum colony count category as defined by Griffith et al, 2015

    Time frame: Day 1 to Day 84

  4. Change from baseline in Quality of Life - Bronchiectasis (QOL-B) Respiratory Domain at Day 84

    QOL-B Domain scores range from 0 to 100, with higher scores indicating better health-related quality of life

    Time frame: Day 1 to Day 84

  5. Change from baseline in MACrO2 PRO at Day 84

    MACrO2 scores range from 0 to 100, with lower scores indicating better symptom-related quality of life

    Time frame: Day 1 to Day 84

  6. Sputum culture conversion by Day 56

    Defined as 2 consecutive negative cultures collected one month apart without intervening or subsequent positives

    Time frame: Day 1 to Day 56

Secondary outcomes

  1. Patient Global Impression of Change (PGI-C) at Day 84

    The Patient Global Impression of Change Scale has a minimum value of 1 and a maximum value of 7. For this scale, higher scores indicate a worse outcome.

    Time frame: Day 1 to Day 84

  2. Patient Global Impression of Severity (PGI-S) at Day 84

    The Patient Global Impression of Severity Scale measures severity of a patient's overall status over the previous 7 days. The responses on this scale have a minimum value of 'None' and a maximum value of 'Very severe' related to severity. For this scale, higher scores ('Very severe') indicate a worse outcome.

    Time frame: Day 1 to Day 84

  3. Physician Visual Analog Scale (VAS) - Global at Day 84

    The Physician Visual Analog Scale - Global has a minimum value of 0 and a maximum value of 10. For this scale, higher scores indicate a worse outcome.

    Time frame: Day 1 to Day 84

  4. Physician Visual Analog Scale (VAS) - Respiratory at Day 84

    The Physician Visual Analog Scale - Respiratory has a minimum value of 0 and a maximum value of 10. For this scale, higher scores indicate a worse outcome.

    Time frame: Day 1 to Day 84

  5. NTM Symptoms Scale (NTM-SS) Questionnaire at Day 84

    The Non-tuberculous Mycobacteria Symptoms Scale measures symptoms within the previous 7 days including respiratory, fatigue, temperature, appetite/weight, cognition/mood, and sleep. Questions on this scale have a minimum value of 'Never' and a maximum value of 'Always' related to the prevalence of symptoms. For this scale, higher scores ('Always') indicate a worse outcome.

    Time frame: Day 1 to Day 84

  6. Time to growth in liquid medium

    Measured at Days 14, 28, 42, 56, and 84

    Time frame: Day 1 to Day 84

  7. Time to first negative sputum culture

    Time frame: Day 1 to Day 84

  8. Proportion of patients with an on-treatment MABC isolate demonstrating decreasing sensitivity to EBO

    Time frame: Day 1 to Day 84

  9. Sputum culture conversion by Day 84

    Defined as 2 consecutive negative cultures one month apart without intervening or subsequent positives

    Time frame: Day 1 to Day 84

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • National Cancer Institute. (2017). Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. https://doi.org/10.33329/ctcae.v5.0
  • Bowman CJ, Becourt-Lhote N, Boulifard V, Cordts R, Corriol-Rohou S, Enright B, Erkman L, Harris J, Hartmann A, Hilpert J, Kervyn S, Mattson B, Morford L, Muller M, Powell M, Sobol Z, Srinivasan R, Stark C, Thompson KE, Turner KJ, Barrow P. Science-Based Approach to Harmonize Contraception Recommendations in Clinical Trials and Pharmaceutical Labels. Clin Pharmacol Ther. 2023 Feb;113(2):226-245. doi: 10.1002/cpt.2602. Epub 2022 May 5. PubMed 35388453 ↗
  • Kaneko T, Otoshi R, Sekine A, Baba T, Yamada C, Haga S, Tagami Y, Sawazumi T, Takemura T, Komatsu S, Hagiwara E, Ogura T. Drug-related pneumonitis caused by amikacin liposome inhalation suspension: One pathologically proven case and single-center experience. Respir Investig. 2024 Jul;62(4):513-516. doi: 10.1016/j.resinv.2024.04.003. Epub 2024 Apr 13. PubMed 38615375 ↗
  • Rimal B, Lippincott CK, Panthi CM, Xie Y, Keepers TR, Alley M, Lamichhane G. Efficacy of epetraborole against Mycobacteroides abscessus in a mouse model of lung infection. Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0064824. doi: 10.1128/aac.00648-24. Epub 2024 Jul 17. PubMed 39016592 ↗
  • Li L, Henkle E, Youngquist BM, Seo S, Hamed K, Melnick D, Lyon CJ, Jiang L, Zelazny AM, Hu TY, Winthrop KL, Ning B. Serum Cell-Free DNA-based Detection of Mycobacterium avium Complex Infection. Am J Respir Crit Care Med. 2024 May 15;209(10):1246-1254. doi: 10.1164/rccm.202303-0401OC. PubMed 38190702 ↗
  • Griffith DE, Adjemian J, Brown-Elliott BA, Philley JV, Prevots DR, Gaston C, Olivier KN, Wallace RJ Jr. Semiquantitative Culture Analysis during Therapy for Mycobacterium avium Complex Lung Disease. Am J Respir Crit Care Med. 2015 Sep 15;192(6):754-60. doi: 10.1164/rccm.201503-0444OC. PubMed 26068042 ↗
  • Eckburg PB, Clarke D, Long J, et al. 2022. Tolerability and pharmacokinetics of oral epetraborole at the predicted therapeutic dosage for Mycobacterium avium complex (MAC) lung disease: a phase 1b dose-ranging and food effect study. In ID week. Washington DC
  • Griffith DE, Daley CL. Treatment of Mycobacterium abscessus Pulmonary Disease. Chest. 2022 Jan;161(1):64-75. doi: 10.1016/j.chest.2021.07.035. Epub 2021 Jul 24. PubMed 34314673 ↗
  • Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr, Andrejak C, Bottger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis. 2020 Aug 14;71(4):e1-e36. doi: 10.1093/cid/ciaa241. PubMed 32628747 ↗
  • Strnad L, Winthrop KL. Treatment of Mycobacterium abscessus Complex. Semin Respir Crit Care Med. 2018 Jun;39(3):362-376. doi: 10.1055/s-0038-1651494. Epub 2018 Aug 2. PubMed 30071551 ↗
  • Diel R, Ringshausen F, Richter E, Welker L, Schmitz J, Nienhaus A. Microbiological and Clinical Outcomes of Treating Non-Mycobacterium Avium Complex Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Review and Meta-Analysis. Chest. 2017 Jul;152(1):120-142. doi: 10.1016/j.chest.2017.04.166. Epub 2017 Apr 28. PubMed 28461147 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Dec 24, 2025
StartActual
Mar 30, 2026
Primary completionEst.
Dec 2027
CompletionEst.
May 2028
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07301320
Lead sponsor
Kevin Winthrop
Collaborators
AN2 Therapeutics, Inc
Responsible party
Kevin Winthrop (Professor, Oregon Health and Science University) — Sponsor-investigator
First posted
Dec 24, 2025
Start date
Mar 30, 2026
Primary completion
Dec 2027 (estimated)
Completion
May 2028 (estimated)
Last update
May 6, 2026

Study contacts

Felicity Coulter, PhD
Contact
rebound@ohsu.edu
503-494-2565
Brandy Peacock, DAOM, MAcOM
Contact
rebound@ohsu.edu
(503) 494-8022
Kevin L Winthrop, MD, MPH
principal investigator · Oregon Health and Science University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epetraborole

Start the discussion